Zevenbergen Capital Investments LLC Has $2.86 Million Stock Holdings in Abbott Laboratories $ABT

Zevenbergen Capital Investments LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 0.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,009 shares of the healthcare product maker’s stock after buying an additional 195 shares during the quarter. Zevenbergen Capital Investments LLC’s holdings in Abbott Laboratories were worth $2,857,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ABT. Kelly Financial Services LLC bought a new stake in Abbott Laboratories during the 1st quarter worth about $216,000. Bank Pictet & Cie Europe AG raised its holdings in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after purchasing an additional 2,774 shares during the last quarter. Edge Financial Advisors LLC raised its holdings in Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker’s stock worth $336,000 after purchasing an additional 81 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Abbott Laboratories during the 4th quarter worth about $84,418,000. Finally, Cerity Partners LLC raised its holdings in Abbott Laboratories by 49.8% during the 1st quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker’s stock worth $199,939,000 after purchasing an additional 501,200 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on ABT shares. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price target for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Leerink Partners assumed coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target for the company. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Morgan Stanley upped their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $144.47.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is owned by insiders.

Abbott Laboratories Trading Up 1.0%

Shares of Abbott Laboratories stock opened at $133.92 on Friday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The stock has a market cap of $233.08 billion, a P/E ratio of 16.78, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The business’s 50 day moving average is $130.41 and its 200-day moving average is $131.29.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the prior year, the business posted $1.14 EPS. The business’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.